Press Release Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights 13 hours ago
Press Release Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy Aug 5